MLTX

MoonLake Immunotherapeutics

Add to Watchlist

Advanced Chart

50.460

-1.89(-3.610%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

52.570

Open

52.460

VWAP

Vol

1.18M

Mkt Cap

3.24B

Low

46.120

Amount

EV/EBITDA(TTM)

Total Shares

62.87M

2.96B

EV/OCF(TTM)

P/S(TTM)

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

11 Analyst Rating

50.42% Upside

Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 75.90 USD with a low forecast of 61.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

50.42% Upside

Current: 50.460

Low

61.00

Averages

75.90

High

100.00

50.42% Upside

Current: 50.460

Low

61.00

Averages

75.90

High

100.00

Rothschild & Co Redburn

Neutral

initiated

$65

2025-07-28

New

Reason

Rothschild & Co Redburn

Price Target

$65

2025-07-28

New

initiated

Neutral

Reason

Rothschild & Co Redburn initiated coverage of MoonLake Immunotherapeutics with a Neutral rating and $65 price target.

Wolfe Research

Peer Perform -> Outperform

upgrade

$61

2025-05-19

Reason

Wolfe Research

Price Target

$61

2025-05-19

upgrade

Peer Perform -> Outperform

Reason

Wolfe Research upgraded MoonLake Immunotherapeutics to Outperform from Peer Perform with a $61 price target.

Wolfe Research

Andy Chen

Peer Perform

Outperform

upgrade

$61

2025-05-19

Reason

Wolfe Research

Andy Chen

Price Target

$61

2025-05-19

upgrade

Peer Perform

Outperform

Reason

Wolfe Research analyst Andy Chen upgraded MoonLake Immunotherapeutics to Outperform from Peer Perform with a $61 price target. While the firm says it "could not easily convince ourselves" that MoonLake would see a greater than 25% delta on efficacy, which it says "would be a homerun scenario for the stock for beating the buyside bar," with its "more defensible" base case at 24% delta on efficacy, the firm notes that it lands closer to the 25% "bull bar" than the 22% "bear bar." The firm sees 24% as "a fundamentally good scenario where the drug is clearly differentiated from UCB's Bimzelx on efficacy" and argues that after the September event, good data "should replenish the M&A premium and drive upward revisions on the back of sonelokimab's commercial advantage."

RBC Capital

Brian Abrahams

Buy

Initiates

$67

2025-03-18

Reason

RBC Capital

Brian Abrahams

Price Target

$67

2025-03-18

Initiates

Buy

Reason

RBC Capital initiated coverage of MoonLake Immunotherapeutics with an Outperform rating and $67 price target. The firm's analysis and feedback provides confidence lead drug sonelokimab will show clear, statistically significant benefits in the mid-year phase III hidradenitis suppurativa readout and 22%-24% placebo adjusted HiSCR75 delta, reflecting an incrementally better profile vs. currently marketed competitor bime, positioning sonelokimab as an early-line biologic of choice that helps drive a $2.5B per year sales opportunity, the analyst tells investors in a research note. The market opportunity in HS is likely to be underestimated, enabling long-term appreciation, the firm argues.

Goldman Sachs

Richard Law

Strong Buy

Maintains

$82 → $73

2025-02-27

Reason

Goldman Sachs

Richard Law

Price Target

$82 → $73

2025-02-27

Maintains

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Maintains

$62 → $66

2025-02-27

Reason

Needham

Serge Belanger

Price Target

$62 → $66

2025-02-27

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for MoonLake Immunotherapeutics (MLTX.O) is -17.88, compared to its 5-year average forward P/E of -21.53. For a more detailed relative valuation and DCF analysis to assess MoonLake Immunotherapeutics 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-21.53

Current PE

-17.88

Overvalued PE

-6.31

Undervalued PE

-36.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.47

Current EV/EBITDA

-14.26

Overvalued EV/EBITDA

-5.30

Undervalued EV/EBITDA

-25.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00